A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Influenza A virus H7N9 vaccines (Primary)
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 22 Feb 2018 Planned primary completion date changed from 3 Jun 2019 to 20 May 2019.
- 21 Dec 2017 Status changed from not yet recruiting to recruiting.
- 27 Oct 2017 New trial record